JNJ-63733657

DRUG5 trials

Sponsors

Janssen - Cilag International, Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

Alzheimer DiseaseCognitive DysfunctionDementiaEarly Alzheimer's DiseaseHealthy

Phase 1

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

CompletedNCT03375697

Janssen Research & Development, LLCAlzheimer Disease

Start: 2017-12-22End: 2019-12-16Updated: 2025-04-27

A Study of JNJ-63733657 in Healthy Japanese Participants

CompletedNCT03689153

Janssen Pharmaceutical K.K.Healthy

Start: 2018-09-28End: 2019-07-11Updated: 2025-04-28

A Study of JNJ-63733657 in Healthy Chinese Participants

CompletedNCT05407818

Janssen Research & Development, LLCHealthy

Start: 2022-06-27End: 2022-11-07Updated: 2025-04-27

Phase 2

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

TerminatedNCT04619420

Janssen Research & Development, LLCAlzheimer Disease, Cognitive Dysfunction, Dementia

Start: 2021-01-06End: 2026-03-03Updated: 2026-04-03

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease

Active, not recruitingCTIS2022-501188-42-00

Janssen - Cilag InternationalEarly Alzheimer's Disease

Start: 2021-04-15Target: 195Updated: 2025-12-16

Related Papers

Mechanistic Population Pharmacokinetic-Pharmacodynamic Model of the Tau-Targeted Antibody Posdinemab in Healthy Participants and Participants with Alzheimer's Disease.

2025-12-22

Assessment of Association of Tau PET Spatial Patterns with Cognitive Domains in Participants with Early Alzheimer's Disease in the Phase 2 Auτonomy Trial

Alzheimer s & Dementia2025-12-01

Assessment of Association of Tau PET Spatial Patterns with Cognitive Domains in Participants with Early Alzheimer's Disease in the Phase 2 Auτonomy Trial

Alzheimer s & Dementia2025-12-01

Analysis of reasons for screen failure by participant race in the Phase 2 Auτonomy study in early Alzheimer's disease

Alzheimer s & Dementia2025-12-01

A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Posdinemab (JNJ-63733657) in Healthy Chinese Adults.

2025-10-13

In‐vivo Braak Stage Distribution of Screened and Randomized Participants from Auτonomy, a Phase 2 Anti‐p‐tau Monoclonal Antibody Trial in Early Symptomatic Alzheimer’s Disease

Alzheimer s & Dementia2023-12-01

In‐vivo Braak Stage Distribution of Screened and Randomized Participants from Auτonomy, a Phase 2 Anti‐p‐tau Monoclonal Antibody Trial in Early Symptomatic Alzheimer’s Disease

Alzheimer s & Dementia2023-12-01

Associations of Age and Sex with Levels of Tau PET in Screened Participants from Auτonomy, a Phase 2 Anti‐p‐tau Monoclonal Antibody Trial in Early Symptomatic Alzheimer’s Disease

Alzheimer s & Dementia2023-12-01

Associations of Age and Sex with Levels of Tau PET in Screened Participants from Auτonomy, a Phase 2 Anti‐p‐tau Monoclonal Antibody Trial in Early Symptomatic Alzheimer’s Disease

Alzheimer s & Dementia2023-12-01

Development of immunoprecipitation – two-dimensional liquid chromatography – mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients

Journal of Chromatography A2021-05-2822 citations